(Q36530170)

14 August 2017

1 reference

title

ACE inhibitors and angiotensin receptor antagonists and the incidence of new-onset diabetes mellitus: an emerging theme (English)

1 reference

14 August 2017

David Aguilar

1

1 reference

ORCID Public Data File 2021

author name string

Scott D Solomon

series ordinal

2

1 reference

14 August 2017

language of work or name

1 reference

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

66

1 reference

14 August 2017

issue

9

1 reference

14 August 2017

page(s)

1169-1177

1 reference

The evolving diabetes burden in the United States

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666090-00001

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200666090-00001

Diabetes mellitus. Report of a WHO Study Group

21 January 2018

1 reference

12 December 2020

Angiotensin converting enzyme inhibitors and modulation of skeletal muscle insulin resistance

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity

1 reference

12 December 2020

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

12 December 2020

Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat.

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes

1 reference

12 December 2020

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

1 reference

12 December 2020

Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

12 December 2020

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

12 December 2020

1 reference

12 December 2020

Adverse prognostic significance of new diabetes in treated hypertensive subjects

1 reference

12 December 2020

Angiotensin-converting-enzyme inhibition in stable coronary artery disease

1 reference

12 December 2020

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

1 reference

12 December 2020

Retinoid x receptor heterodimers in the metabolic syndrome

1 reference

12 December 2020

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

12 December 2020

Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition

1 reference

12 December 2020

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

1 reference

12 December 2020

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

1 reference

12 December 2020

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

12 December 2020

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

12 December 2020

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

1 reference

12 December 2020

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

12 December 2020

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

12 December 2020

Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure.

1 reference

12 December 2020

Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

1 reference

12 December 2020

Crosstalk between insulin and angiotensin II signalling systems

1 reference

12 December 2020

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

12 December 2020

Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.

1 reference

12 December 2020

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

12 December 2020

Ramipril and the development of diabetes.

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

1 reference

12 December 2020

Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure

1 reference

12 December 2020

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

12 December 2020

Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

1 reference

12 December 2020

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

1 reference

12 December 2020

ACE inhibition and glucose transport in insulinresistant muscle: roles of bradykinin and nitric oxide.

1 reference

12 December 2020

Lifetime Risk for Diabetes Mellitus in the United States

1 reference

12 December 2020

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

12 December 2020

Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats

1 reference

12 December 2020

Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP).

1 reference

12 December 2020

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

12 December 2020

The association of heart failure with insulin resistance and the development of type 2 diabetes

1 reference

12 December 2020

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

1 reference

12 December 2020

10.2165/00003495-200666090-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1028359242

0 references

1 reference